News

   

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

ENHANCE-2 Screening Complete with Full Enrollment Expected in…

Genmab and Synaffix Enter into License Agreement for ADC Technology

Synaffix to provide access to proprietary antibody-drug conjugate…

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona…

Novo Holdings participates in EUR 110 million first closing of Sound Bioventures Fund I

Copenhagen, Denmark – Novo Holdings, a leading international…

Novo Holdings to acquire Ritedose

Novo Holdings A/S (“Novo Holdings”) today announced that…

AMSilk Partners with Mercedes-Benz to Present a Sustainable Bio-Based Product

The use of a biotechnology-based and certified-vegan…

EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)

OSLO/LONDON, 22 December 2021: Christmas came early at EXACT…

Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes

COPENHAGEN, DENMARK — Novo Holdings, a leading international…

EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®

OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx”…

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

Chord Therapeutics was launched by Omega Funds in October…

Futura provides US regulatory and commercial update for MED3000

Futura Medical plc (AIM: FUM), a pharmaceutical company developing…

Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction

Study Supports Ongoing Phase 3 Program and Planned NDA Submission LONDON…

Novo Nordisk Fonden: New international research center to drive future stem cell-derived medicines

Stem cell medicine is delivering hope for new treatments across…

Novo Nordisk Foundation – New international research center to drive future stem cell-derived medicines

A grant from the Novo Nordisk Foundation of up to 300 million…

FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

TARPEYO (budesonide) delayed release capsules is the first…

2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon

Management of Destiny Pharma (DEST), the AIM listed infection…

ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of world’s smallest insulin pump across Europe

New investor, Partners in Equity – joins existing investors…

Depixus Raises USD 35.4M in Series A Financing

The financing will support development of a commercial instrument…

Biocomposites year of international growth and product advancement

Expansion into new geographies and enhanced approval for STIMULAN…

Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data

Egetis concludes, based on recent regulatory interactions,…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

Get in touch
© Optimum Strategic Communications.